Decreased 5-hydroxytryptamine turnover in striatum and other brain regions after administration of 5-methoxy-3-(di-n-propylamino)chroman to rats.
5-Methoxy-3-(di-n-propylamino)chroman (5-MeO-DPAC) caused a dose-dependent decrease in the accumulation of 5-hydroxytryptophan after decarboxylase inhibition in rat striatum, hippocampus and frontal cortex. The decreased 5-hydroxytryptamine (5-HT) turnover may have resulted from activation of 5-HT receptors on cell bodies of 5-HT neurons that project to the striatum and other brain regions, since 5-MeO-DPAC had earlier been reported to lack affinity for striatal binding sites.
Fuller
R W
RW
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Perry
K W
KW
Ward
J S
JS
D006916:5-Hydroxytryptophan / Q000378:metabolism*; D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D001923:Brain Chemistry / Q000187:drug effects*; D002839:Chromans / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism
D001578:Benzopyrans; D002839:Chromans; D011985:Receptors, Serotonin; C054083:5-methoxy-3-(di-n-propylamino)chroman; D006916:5-Hydroxytryptophan